Phase 4
Completed N=54
A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Source: ClinicalTrials.gov NCT00527592 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Feb 2010
Primary outcomePrimary: Comfort Immediately After Dosing — 7.8; 7.1 Units on a scale
Summary
The purpose of this study is to compare the comfort of Travatan Z in one eye and Xalatan in the opposite eye in patients with primary open-angle glaucoma or ocular hypertension.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comfort Immediately After Dosing |
7.8; 7.1 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older.
- Clinical diagnosis of ocular hypertension, primary open-angle, pigment dispersion, or exfoliation glaucoma in both eyes.
- Best corrected visual acuity of 20/200 Snellen or better in each eye.
- Intraocular pressure within protocol-specified range.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Any abnormality preventing reliable applanation tonometry in the study eye(s).
- Any eye conditions or procedures as specified in protocol.
- Progressive retinal or optic nerve disease from any cause.
- Use of contact lenses in the study eye(s).
- Other protocol-defined exclusion criteria may apply.
Data sourced from ClinicalTrials.gov (NCT00527592). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.